Smart scans and blood tests could guide lymphoma treatment
NCT ID NCT04604067
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial is testing whether using ctDNA blood tests and PET scans can help doctors choose the right treatment for people with diffuse large B-cell lymphoma. About 260 participants will receive different combinations of standard chemotherapy (R-CHOP) plus the targeted drug acalabrutinib, based on their genetic markers and early response. The goal is to see if this personalized approach can improve outcomes and reduce unnecessary treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Acalabrutinib combined with R-CHOP chemotherapy
What this could lead to
If successful, this could lead to more personalized treatment for DLBCL, potentially improving survival and reducing unnecessary chemotherapy for some patients.
What could go wrong
This is an early-phase trial with multiple treatment groups, so results may not apply to all patients. The added drug acalabrutinib may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Universitaria Maggiore della Carita di Novara
Novara, 20503, Italy
-
Centre Hospitalier Universitaire Vaudois
Lausanne, CH-1011, Switzerland
-
City Hospital Triemli
Zurich, CH-8063, Switzerland
-
Hopital Fribourgeois
Fribourg, 1708, Switzerland
-
Hopitaux Universitaire de Genève (HUG)
Geneva, 1211, Switzerland
-
Inselspital, Bern
Bern, CH-3010, Switzerland
-
Istituto Oncologico della Svizzera Italiana
Bellinzona, 6500, Switzerland
-
Kantonsspital Aarau
Aarau, CH-5001, Switzerland
-
Kantonsspital Baden (Baden/Brugg)
Baden, 5404, Switzerland
-
Kantonsspital Graubünden
Chur, 7000, Switzerland
-
Kantonsspital Luzern
Luzerne, CH-6000, Switzerland
-
Kantonsspital Olten
Olten, CH-4600, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
Ospedale Papa Giovanni XXIII
Bergamo, 24127, Italy
-
Policlinico Agostino Gemelli
Roma, 00168, Italy
-
Réseau Hospitalier Neuchâtelois (RHNe)
Neuchâtel, 2000, Switzerland
-
St. Claraspital
Basel, 4058, Switzerland
-
UniversitätsSpital Zürich
Zurich, 8091, Switzerland